english.prescrire.org > Spotlight > Archives : 2026 > Lecanemab (Leqembi°) in early Alzheimer's disease

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

Lecanemab (Leqembi°) in early Alzheimer's disease

 Marketing Authorisations  The European Medicines Agency (EMA) initially issued a negative opinion on the marketing authorisation application for lecanemab. After an appeal by the pharmaceutical company and re-examination of the data, particularly in certain subgroups of patients, the EMA issued a positive opinion.
Full article available for download by subscribers

 ©Prescrire 1 April 2026

Source: "Lecanemab (Leqembi°) in early Alzheimer's disease" Prescrire Int 2026; 35 (280): 89-94. Subscribers only.

Filet

Enjoy full access to Prescrire International, and support independent information

 

Share
Share on  Facebook  
 
 
See also:
 
"Look to the past"
Prescrire Int 2026;
35 (280): 87. 
FREE